Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × regorafenib × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 39 Carcinoma, Hepatocellular 15 Rectal Neoplasms 8 Neoplasm Metastasis 8 Colonic Neoplasms 7 Gastrointestinal Stromal Tumors 6 Ovarian Neoplasms 5 Sarcoma 4 Melanoma 4 Osteosarcoma 3 Glioblastoma 3 Cholangiocarcinoma 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Liver Neoplasms 2 Gallbladder Neoplasms 2 Fatigue 2 Esophageal Neoplasms 2 Colorectal Cancer Metastatic 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1 Thyroid Neoplasms 1 Thymoma 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1 Solid Malignant Tumors 1 Small Cell Lung Carcinoma 1 Rhabdomyosarcoma 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 13 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 7 Irinotecan 7 Trastuzumab 6 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Sunitinib 4 Metformin 4 Gefitinib 4 Erlotinib Hydrochloride 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Ramucirumab 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929616 2019-06-25

RegARd-C

Jules Bordet Institute

Phase 2 Completed

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡